Government of Belgium   Report issue

Government Phase 1 Phase 2 Phase 3 Phase 4
Founded: Brussels Belgium (1839)

Organization Overview

First Clinical Trial
2002
NCT00115479
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Agentschap voor Innovatie door Wetenschap en Technologie, Project Toegepast Biomedisch onderzoek met een primair Maatschappelijke finaliteit. | Anticancer Fund, Belgium | Belgian Government | Fund for Scientific Research, Flanders, Belgium | Funds for Research in Ophthalmology (FRO) of Belgium | National Institute for Health and Disability Insurance (NIHDI), Belgium | Research Foundation Flanders

Active Ingredients

Drugs in Phase 4 Trials (4)

azithromycin (zithromax) (3 trials)

cyclosporine (sandimmune) (1 trial)

tranexamic acid (cyklokapron) (1 trial)

urea (1 trial)

Drugs in Phase 3 Trials (17)

acetylsalicylic acid (aspirin) (2 trials)

albendazole (Albenza) (1 trial)

amodiaquine (camoquin) (1 trial)

artesunate (2 trials)

autologous fecal microbiota (2 trials)

clindamycin (cleocin) (1 trial)

coartem (1 trial)

human fecal microbiota (Reybota) (2 trials)

insulin lispro (humalog) (1 trial)

ketorolac (acuvail) (1 trial)

lisdexamfetamine (vyvanse) (1 trial)

lumefantrine (Coartem) (1 trial)

piperaquinoline (1 trial)

praziquantel (biltricide) (1 trial)

pyrimethamine (daraprim) (1 trial)

quinine (qualaquin) (1 trial)

sulfadoxine (1 trial)

Drugs in Phase 2 Trials (20)

68ganota-anti-her2 vhh1 (1 trial)

abiraterone (zytiga) (1 trial)

azacitidine (vidaza) (1 trial)

beetroot juice (1 trial)

curcumin (1 trial)

cyclophosphamide (cytoxan) (1 trial)

decitabine (dacogen) (1 trial)

enzalutamide (xtandi) (1 trial)

escitalopram (lexapro) (1 trial)

insulin human (humulin) (2 trials)

lansoprazole (prevacid) (1 trial)

letrozole (femara) (1 trial)

megestrol (megace) (1 trial)

nitroglycerin (transderm-nitro) (1 trial)

oxytocin (syntocinon) (2 trials)

pembrolizumab (keytruda) (1 trial)

pioglitazone (actos) (1 trial)

propranolol (inderal) (1 trial)

tretinoin (Retin-A) (1 trial)

vitamin d3 (1 trial)

Drugs in Phase 1 Trials (10)

aprepitant (Emend) (1 trial)

auranofin (ridaura) (1 trial)

captopril (capoten) (1 trial)

celecoxib (celebrex) (1 trial)

disulfiram (antabuse) (1 trial)

itraconazole (sporanox) (1 trial)

minocycline (minocin) (1 trial)

ritonavir (Norvir) (1 trial)

sertraline (zoloft) (1 trial)

temozolomide (temodar) (1 trial)

Drugs in Other Trials (9)

Anti-thymocyte Globulin (Rabbit) (Thymoglobulin) (1 trial)

desogestrel (Mercilon) (1 trial)

ethinyl estradiol (Estinyl) (1 trial)

famotidine (pepcid) (1 trial)

fexofenadine (allegra) (1 trial)

lactose (1 trial)

progestin (1 trial)

sirolimus (rapamune) (1 trial)

tacrolimus (prograf) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Attention Deficit Disorder with Hyperactivity (Phase 3)

Breast Neoplasms (Phase 3)

Bronchiolitis (Phase 4)

Bronchiolitis Obliterans (Phase 4)

Bronchitis (Phase 4)

Carcinoma (Phase 2)

Carcinoma, Hepatocellular (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Colonic Neoplasms (Phase 3)

Conjunctivitis, Allergic (Phase 4)

Critical Illness (Phase 3)

Depression (Phase 2)

Depressive Disorder (Phase 2)

Endometrial Neoplasms (Phase 2)

Glioblastoma (Phase 1)

Hemangiosarcoma (Phase 2)

Hemorrhage (Phase 4)

Hyperglycemia (Phase 3)

Keratoconjunctivitis (Phase 4)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 2)

Malaria (Phase 3)

Recurrence (Phase 3)

Respiratory Tract Infections (Phase 4)

Surgical Wound (Phase 3)

Syndrome (Phase 4)

Uterine Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 32
  • # of Trial APIs: 60